Kuros Biosciences ^Peer

Kuros Biosciences is a biotechnology company based in Switzerland, specializing in advanced biologic technologies for bone healing and spinal fusion. Founded in 2016 through a merger involving Cytos Biotechnology Ltd., the company operates globally with facilities in the Netherlands and the United States. Kuros is listed on the SIX Swiss Stock Exchange under the symbol KURN.

The company develops innovative solutions for spinal fusion surgeries, including MagnetOs, a synthetic bone graft used in over 10,000 procedures worldwide. Another key product is Fibrin-PTH, a drug-biologic combination currently in Phase 2 clinical trials in the U.S. for enhancing bone regeneration. Kuros emphasizes scientific rigor and aims to alleviate the societal and economic burden of spine-related pain through its evidence-based approach and ongoing clinical trials. With a commitment to innovation, Kuros actively participates in global medical conferences and collaborates with research-driven medical centers.